Why IMU is a multi multi bagger, page-29392

Hi HC punters,
Please find response below from Team Imugene .....this was in relation to some questions that was posed to them via email.....make of it what you will
- guess this data that everybody keeps taking about shall light the way - or not
…..they have on a few occasions replied that they are acutely aware of shareholder sentiment - unfortunately at this phase in the game - it’s testing
......still hoping for a favourable outcome for all involved






Dear ___
Under the selective disclosure obligations of the ASX we are unable to respond to enquiries in a private email about matters which are not in the public domain especially assertions and allegations on social media sites/forums.

However, we would like to address some inaccuracies in your email.
1. Mr Hopper and Dr Fong did not seek to sell VAXINIA company to Imugene - they were in the process of a private financing in the U.S., when IMU approached them seeking to acquire the technology

; 2. Mr Hopper has never sold $35m of shares to retail shareholders;

3. An EGM was held on 7 Sept 2021 which approved the issue of IND related milestone shares to Mr Hopper who abstained from voting. The Resolutions were overwhelmingly carried with 96.8% approval;

4. The IND was not late - it was received in the US on 30 June 2021, which was 1st July in Australia, please see announcement released on 2 July 2021: https://wcsecure.weblink.com.au/pdf/IMU/02391061.pdf ;

5. The market has been updated on CF33 programs more than 12 times over the past 12 months; please see ASX announcements on our website https://imugene.com/investors/asx-announcements/;

6. CHECKvacc status and completion was announced in September 2023 Quarterly, please see link https://wcsecure.weblink.com.au/pdf/IMU/02733219.pdf, here is an exert: “The trial is focused on recruiting patients with triple-negative breast cancer (TNBC) and is aimed to assess the safety of intra-tumoral administration of CF33-hNIS-antiPDL1 for metastatic TNBC. After completion of the current cohort 4, the data derived from this trial will be used to inform our other CF33 clinical developments, and resources and finances from this study will be re directed to our priority programs.”

Best Regards,
Imugene